Exabis Library
Welcome to the e-CCO Library!
P465: Do infliximab trough levels differ between adult and paediatric patients with Crohn’s disease in clinical remission?
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P465: Efficacy of ustekinumab for induction and maintenance of histological healing in patients with Crohn's disease
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P465: Health-related quality of life from the Inflammatory Bowel Disease Questionnaire in patients with ulcerative colitis treated with etrasimod in the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P465: Indication-specific feasibility assessment of a placebo-controlled randomised mesalazine withdrawal study for paediatric patients with ulcerative colitis
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P465: Is golimumab serum level predictive of clinical remission after intensification for loss of response in patients with ulcerative colitis?
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P465: One year endoscopic and histologic outcomes to tofacitinib therapy in refractory ulcerative colitis
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P465: UC trial designed more than 5 years ago in the light of the EMA guideline on the development of new medicinal products for the treatment of ulcerative colitis
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P466 Is it possible avoid colectomy with rescue dual therapy with vedolizumab plus tacrolimus in ulcerative colitis that losing response to anti-tumour necrosis factor?
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P466: Acetarsol is an effective and safe option in the management of refractory ulcerative colitis
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P466: Acute Severe Ulcerative Colitis in the modern era: biologic therapy-exposed patients and salvage therapy with intensified infliximab.
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P466: Efficacy and safety outcomes in patients with moderate to severe ulcerative colitis stratified by ethnicity and race: a pooled analysis of data from GEMINI 1, VARSITY, and VISIBLE 1
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P466: Real world effectiveness of vedolizumab over one year in inflammatory bowel disease: a meta-analysis
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P466: Real-world effectiveness and safety of golimumab in patients with ulcerative colitis: 52-weeks of post-marketing surveillance data in Japan
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P466: Relapse rates of inflammatory bowel disease patients in deep and clinical remission after discontinuing anti-tumour necrosis factor alpha therapy: a prospective single-centre open-label study
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P466: Tofacitinib for the treatment of ulcerative colitis: Up to 5.4 years of safety data from global clinical trials
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P467 Can induction and maintenance serum vedolizumab levels predict long-term clinical outcome in inflammatory bowel disease (IBD)?
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P467: 5-ASA is not superior to no-maintenance in patients with newly diagnosed Crohn's disease - a nationwide cohort from the epi-IIRN
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P467: A comparison of thiopurines vs. anti-TNF-α therapy in steroid-dependent ulcerative colitis
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P467: Circulating CD8 α4β7+ and CD8b7+ memory T cells as early biomarkers of clinical response to vedolizumab in ulcerative colitis
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P467: Maintenance of quality of life improvement in a phase 3 study of tofacitinib for patients with moderately to severely active ulcerative colitis
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM